DIAMANTE (Nano-Technologies for Autoimmune Disease) is a biotech company focused on the use of plants for producing high value-added molecules.
The company was funded in 2016 with the development of new tools in autoimmune disease diagnosis and now we are growing approaching therapeutics applications.
As an innovation-oriented female company, our value proposition is the creation of novel therapeutic approach for autoimmune diseases based on the restoration of self-tolerance, using plant viruses displaying immunodominant peptides.
The company’s main asset is a specific therapeutic solution for Rheumatoid Arthritis (RA).
Diamante’s technology leverages plant viruses for the production of virus nanoparticles (VNPs) and an innovative therapeutic approach based on the specific induction of the immunological tolerance through the use of specific autoantigenic peptides.
We had pre-clinical evidence of the efficacy of our therapeutic approach and our goal is to enter the human clinical trials by the end of 2023. We are looking for industrial partner to grow together.
Diamante pipeline will explore new therapeutic applications for other autoimmune diseases.
Building the product pipeline for commercial demonstration of Plant Molecular Factories
14 partners, 7 countries, 5 SMEs, 3 public research institutions and 6 universities
Global network for innovators. They equip bold entrepreneurs to disrupt the status quo and create meaningful change. With more than a decade of experience, they proven methodology accelerates the innovation potential of high-growth businesses and startups as they address biggest challenges
One year of acceleration program to boost the business, create new industrial partnership and grow internationally